SIGN IN YOUR ACCOUNT TO HAVE ACCESS TO DIFFERENT FEATURES

FORGOT YOUR PASSWORD?

FORGOT YOUR DETAILS?

AAH, WAIT, I REMEMBER NOW!
+1 786 238 2170

Global Stem Cells GroupGlobal Stem Cells Group

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Press Releases
  • Blog
CONTACT
  • Home
  • Press Releases
  • Cellgenic Announces Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September
June 17, 2025

Cellgenic Announces Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September

Tuesday, August 20, 2024 / Published in Press Releases

Cellgenic Announces Sponsorship of Three Prominent Regenerative Medicine Events in Peru This September

Miami, FL – August 2024 – Cellgenic, a division of Global Stem Cells Group and a global leader in regenerative medicine, is pleased to announce its sponsorship of three major medical events in Peru this September, where the company will prominently feature its advanced exosome and peptide products. This sponsorship underscores Cellgenic’s commitment to expanding its presence in the rapidly growing Latin American market for regenerative medicine.

Event Details:

  • International Regenerative Medicine Conference by ISSCA – September 6-7, 2024: Taking place at the prestigious Hilton Hotel, this event, hosted by the International Society for Stem Cell Application (ISSCA), will gather leading experts from around the world to discuss the latest advancements in stem cell research and regenerative therapies.
  • AMDAL 2024 – September 14-15, 2024: Held at the Sol de Oro Hotel in Miraflores, AMDAL 2024 will focus on the latest innovations in dermatology and laser treatments. This event will bring together professionals from across the medical and aesthetic fields to explore cutting-edge technologies and practices.
  • MDE24 International Congress of Medicine and Aesthetic Dermatology – September 20-21, 2024: This event, set to take place at the ESAN Convention Center, will highlight groundbreaking developments in aesthetic dermatology and medical treatments, attracting participants from across the globe.

These events will feature a diverse lineup of international and local speakers, as well as participating doctors from Peru and neighboring regions. As a sponsor, Cellgenic will have a unique opportunity to introduce its pioneering exosome technology to the attending medical professionals, demonstrating why exosomes represent a promising and expanding market in Latin America.

“Cellgenic is honored to participate in these prestigious events, where we will showcase our latest innovations in regenerative medicine,” said Benito Novas, Founder of Global Stem Cells Group. “We are particularly excited to introduce our exosome products to a new audience in this region. Additionally, we are leveraging these platforms to officially launch our new line of peptides, which we believe could offer significant benefits to medical professionals and patients alike.”

Exosomes, derived from mesenchymal stem cells, have been increasingly recognized for their potential in enhancing regenerative processes, offering new avenues for treatment in areas such as aesthetic medicine, orthopedics, and chronic conditions. The Latin American market, with its growing focus on advanced medical therapies, might be poised for significant growth in the adoption of exosome-based treatments.

Sarah Barroso, Director of Cellgenic, emphasized the strategic importance for the company’s presence in Peru. “Doctors in Peru have consistently shown a strong interest in our exosome products, and our participation in these conferences represents a crucial opportunity for us to expand our footprint in this promising market,” Barroso stated. “We are confident that our exosomes and peptides will meet the evolving needs of healthcare professionals in the region, providing them with innovative tools to improve patient outcomes.”

About Cellgenic

As a division of Global Stem Cells Group, Cellgenic is driven by a commitment to lead the way in regenerative medicine. By continuously expanding its product offerings, including exosomes and peptides, and staying at the forefront of scientific research, Cellgenic aims to meet the increasing demand for advanced, effective, and safe therapies in Latin America and beyond. The potential of exosomes and peptides to revolutionize patient care might position Cellgenic as a key player in this rapidly evolving landscape.

About Global Stem Cells Group

Global Stem Cells Group is a leading provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.

Global Stem Cells Group is a publicly traded company operating under the symbol MSSV. https://finance.yahoo.com/quote/mssv/

To learn more about Global Stem Cells Group, Inc.’s companies visit our website www.stemcellsgroup.com or call +1 305 560 5331

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions, or any other information relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates, and projections about our business based partly on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Therefore, actual outcomes and results may and are likely to differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release, and The Global Stem Cells Group undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release. This press release does not constitute a public offer of any securities for sale. Any securities offered privately will not be or have not been registered under the Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

What you can read next

Stem Cell Training Inc. Announces Alliance with Far Eastern University to Advance in-Office Stem Cell Procedures
Stem Cell Training, Inc. Announces Joint Venture with The Research Center in Tissue Engineering and Cellular Therapy at Maimonides University
Global Stem Cells Group, Inc. Announces Plans to Attend 21st Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Las Vegas, Dec. 15, 2013

Send Us a Message

Contact Home GSCG website

Name(Required)
Email(Required)
Please let us know what's on your mind. Have a question for us? Ask away.
  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

  • Home
  • Our Story
  • Speakers
  • Investors
  • Companies
  • Testimonials
  • Press Releases
  • Blog

Copyright © 2024 Stem Cells Group | All Rights Reserved

CONTACT US

Datran Center 9100 S Dadeland Boulevard, Suite 1500. Miami Fl. 33156 United States

305-560-5337

info@stemcellsgroup.com

STAY CONNECTED

Get the latest news, updates, and promotions. Follow us on our social networks.

Certification issued by ISSCA

TOP